Get the Stockscreener App
13.73
36.62%
3.68
Pre-market:
13.76
0.03
+0.22%
Ventyx Biosciences Inc stock is traded at $13.73, with a volume of 26.78M.
It is up +36.62% in the last 24 hours and up +57.45% over the past month.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
See More
Previous Close:
$10.05
Open:
$15.32
24h Volume:
26.78M
Relative Volume:
6.18
Market Cap:
$979.75M
Revenue:
-
Net Income/Loss:
$-192.96M
P/E Ratio:
-4.1606
EPS:
-3.3
Net Cash Flow:
$-167.04M
1W Performance:
+52.05%
1M Performance:
+57.45%
6M Performance:
+573.04%
1Y Performance:
+444.84%
1-Day Range:
$13.43
$15.34
1-Week Range:
$7.08
$25.00
52-Week Range:
$0.783
$25.00
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Name
Ventyx Biosciences Inc
Sector
Industry
Phone
(760) 407-6511
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Compare VTYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
13.73 | 717.15M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-12-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-12-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-07-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-23 | Downgrade | Stifel | Buy → Hold |
| Nov-07-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Wells Fargo | Overweight |
| Dec-19-22 | Initiated | Goldman | Buy |
| Nov-17-22 | Initiated | Morgan Stanley | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Sep-01-22 | Initiated | H.C. Wainwright | Buy |
| May-09-22 | Initiated | Credit Suisse | Outperform |
| Mar-31-22 | Initiated | Canaccord Genuity | Buy |
| Feb-01-22 | Initiated | Oppenheimer | Outperform |
| Nov-15-21 | Initiated | Jefferies | Buy |
| Nov-15-21 | Initiated | Piper Sandler | Overweight |
View All
Ventyx Biosciences Inc Stock (VTYX) Latest News
Ventyx Biosciences downgraded to Neutral from Buy at UBS - TipRanks
Lilly to acquire Ventyx Biosciences stock for $1.2 billion, Canaccord cuts rating - Investing.com Canada
UBS downgrades Ventyx Biosciences stock to Neutral on Eli Lilly acquisition - Investing.com Canada
Eli Lilly to acquire Ventyx Biosciences stock for $1.2 billion as Clear Street downgrades - Investing.com
Lilly Commits $1.2B to Transform Oral Therapy Landscape with Ventyx Acquisition - geneonline.com
Lilly Inks $1.2bn Deal For Ventyx In Broader Pipeline Expansion - Citeline News & Insights
Significant price jump for US biotech company - medwatch.com
Ventyx downgraded to Market Perform from Outperform at LifeSci Capital - TipRanks
Eli Lilly to Acquire Drug Developer Ventyx for $1.2 Billion, Expanding in Autoimmune Field - Bitget
Lilly to buy Ventyx Biosciences for $1.2 billion - Indian Pharma Post
Shareholder Alert: The Ademi Firm investigates whether Ventyx Biosciences, Inc. is obtaining a Fair Price for its Public Shareholders - Morningstar
Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion, Expanding Inflammation Portfolio - NAI500
Confirming rumours, Lilly to buy Ventyx in $1.2B deal - FirstWord
Eli Lilly confirms plan to buy Ventyx Biosciences in $1.2 billion deal - MSN
Eli Lilly confirms deal to buy Ventyx Biosciences for $14 a share - MSN
Eli Lilly to buy Ventyx Biosciences for $1.2 billion - 104.1 WIKY
Eli Lilly (LLY) Acquires Ventyx Biosciences for $1.2 Billion - GuruFocus
Eli Lilly Confirms Plan To Buy Ventyx Biosciences In $1.2 Billion Deal - Investor's Business Daily
Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14 - TechStock²
Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs - BioPharma Dive
Eli Lilly to buy Ventyx Biosciences for $1.2bn - MLex
Eli Lilly to Acquire Ventyx Biosciences in Cash Deal - TipRanks
Lilly moves beyond blockbuster obesity drugs with $1.2 billion Ventyx buy - Bitget
Lilly moves beyond blockbuster obesity drugs with $1.2 billion Ventyx buy By Reuters - Investing.com
Ventyx Biosciences Signs Multiple Material Agreements - TradingView — Track All Markets
Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus - TechStock²
Eli Lilly (LLY) Set to Acquire Ventyx Biosciences in Cash Deal - GuruFocus
Eli Lilly, IBD Stock Of The Day, Offers Two Entries On Rumored Buyout Rally - Investor's Business Daily
Lilly confirms $1.2B takeover of Ventyx Biosciences - breakingthenews.net
Eli Lilly and Co will acquire all outstanding shares of Ventyx Biosciences in an all-cash transaction at a price of $14.00 per common share. - 富途牛牛
Eli Lilly to acquire Ventyx Biosciences in $1.2B deal - Axios
Eli Lilly to acquire Ventyx Biosciences for $14.00 per share in cash - TipRanks
Lilly to pay $1.2B for Ventyx and its NLRP3 drugs - Endpoints News
Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal - Yahoo! Finance Canada
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases - PR Newswire
Ventyx Stocks Soar Amid Acquisition Talks - StocksToTrade
Eli Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal - Stocktwits
Eli Lilly Shares Surge On Report Of Potential Ventyx Acquisition - Benzinga
Lilly in talks to buy Ventyx Biosciences for more than $1B, WSJ reports - Indianapolis Business Journal
Stocks making the biggest moves midday: Deckers Outdoor, Amgen, Western Digital, Ventyx Biosciences & more - CNBC
Eli Lilly stock climbs on Ventyx buyout talk as dealmaking takes center stage - TechStock²
Eli Lilly (LLY) Nears $1 Billion Acquisition of Ventyx Biosciences (VTYX) - GuruFocus
BRIEF—Ventyx rockets on reports of Lilly buyout - The Pharma Letter
Eli Lilly nears deal for Ventyx Biosciences at $14/shareWSJ - MSN
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - Benzinga
Companies are discussing a deal in which Eli Lilly would pay $14 a share in cash for Ventyx- WSJ - MarketScreener
Ventyx Biosciences stock skyrockets nearly 70% after Eli Lilly offer - medwatch.com
Exclusive | Eli Lilly Nears Deal for Biotech Ventyx - The Wall Street Journal
Stock Movers: Ventyx, Mobileye, Strategy - Bloomberg.com
Ventyx Takeover Talks Boost Stock - timothysykes.com
Stock Market Today: Dow Futures Up, S&P 500 And Nasdaq Slip As ADP Jobs Data Signals Modest Rebound— Mobileye, Penguin Solutions In Focus (UPDATED) - Benzinga
Ventyx Biosciences Inc Stock (VTYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):